New Zealand: common questions

There is no blanket permission for psychedelic therapy. Individual approval for clinical psychedelic treatment. Exceptions, personal-use protections or reduced enforcement do not by themselves authorize treatment services.

Misuse of Drugs Regulations 1977, regulation 22, Psilocybin remains a Class A controlled drug in New Zealand. Medical practitioners may apply to Medsafe for individual approval under regulation 22 to prescribe, supply and administer psychedelics for a defined clinical purpose outside research. The first announced psilocybin approval covered treatment-resistant depression. This is not general prescribing permission or legal retreat access.

Individual practitioners need approval for a defined clinical purpose Psilocybin remains Class A and is not an approved medicine The June 2025 announcement described an individual approval, not general access

We don't have a licensing authority on record for listed providers here.

2 listed; 0 with a license confirmed against an official registry.

TMS and ketamine therapy, Ketamine consultations and treatment.

No stage-specific remote arrangement is documented in these listings. 0 unique listings have a remote-service or support record. Unknown arrangements are not evidence that remote support is unavailable. Preparation and integration are separate from administration; these records do not establish legal permission or clinical eligibility for remote treatment.

No. Laws change often, confirm with the official sources below or a licensed attorney.